The suppression of ovarian function by the new oral contraceptive--Femodene.
Luteinising hormone, oestradiol and progesterone were measured in 36 women commencing Femodene contraception on the first day of menstruation. Of these subjects, 17 were not on any oral contraception during the preceding cycle, the remaining 19 changing from another oral contraceptive formulation. Full measurements were performed in the cycle preceding and the first cycle on Femodene. In another 3 subjects the measurements were made during only one cycle - the first on Femodene. The results confirm ample suppressive effects of Femodene on pituitary and ovarian function. The clinical side effects experienced by the 39 subjects are described.
D003277:Contraceptives, Oral, Combined; D004334:Drug Administration Schedule; D004958:Estradiol / Q000097:blood; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008597:Menstrual Cycle / Q000187:drug effects; D009652:Norpregnenes / Q000008:administration & dosage*; D010060:Ovulation / Q000187:drug effects*; D011374:Progesterone / Q000097:blood
D003277:Contraceptives, Oral, Combined; D009652:Norpregnenes; C055368:Femovan; C033273:Gestodene; D004997:Ethinyl Estradiol; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone